在经历三次自研GLP-1药物折戟的挫折后，全球制药巨头辉瑞（Pfizer）以一场"豪购"宣告其重返千亿美 元减肥药战场的决心。 12月9日，辉瑞与复星医药旗下核心子公司——药友制药正式签署协议，以高达20.85亿美元的总交易 额，获得后者自主研发的口服小分子GLP-1受体激动剂YP05002项目的全球独家权利。这笔交易创下中 国创新药出海早期阶段交易金额的纪录。 根据协议，药友制药将获得1.5亿美元首付款，并有资格获得最高19.35亿美元的里程碑付款及未来的销 售分成。值得注意的是，YP05002目前仅处于澳大利亚I期临床阶段，尚无后期数据支撑。辉瑞为此押 下重注，直接反映了其在明星靶点GLP-1赛道上的深层焦虑与紧迫感——面对诺和诺德、礼来两大巨头 的绝对领先，以及自身核心产品专利悬崖的逼近，辉瑞已别无选择，必须通过资本手段快速卡位。 此举是辉瑞在一个月内第二次重金布局代谢疾病领域。此前，其刚以约100亿美元收购Metsera。接连大 手笔投资，凸显了辉瑞将减肥药确立为未来增长核心的坚定战略。 同时，这笔交易也将中国创新药企的研发价值推至新的高度，中国创新药的出海，正从产品授权迈向更 深层次的全球价值兑现新 ...

Core Insights - Pfizer is making a significant return to the GLP-1 market after three failed attempts with its own GLP-1 drugs, indicating a strong commitment to the weight loss drug sector valued at over $100 billion [1][4] - The company has signed a deal with Fosun Pharma's subsidiary, YaoYao Pharmaceutical, for the global exclusive rights to the oral GLP-1 receptor agonist YP05002 for a total transaction value of up to $2.085 billion, marking a record for early-stage Chinese innovative drug deals [1][2] Group 1: Strategic Intent - Pfizer's acquisition reflects its urgent need to establish a foothold in the GLP-1 space, especially in light of the dominance of competitors like Novo Nordisk and Eli Lilly, and the impending patent cliffs for its core products [1][9] - The company has recently invested heavily in the metabolic disease sector, having acquired Metsera for approximately $10 billion just a month prior, underscoring its strategy to position weight loss drugs as a core growth area [1][4] Group 2: Historical Context - Pfizer has faced multiple setbacks in the GLP-1 field, including the termination of clinical development for Lotiglipron and Danuglipron due to safety concerns and adverse effects observed in trials [4][5][8] - Following these failures, Pfizer attempted to revive Danuglipron with a new formulation but ultimately decided to terminate its development after further safety issues arose [5][8] Group 3: Market Potential - The global market for GLP-1 drugs is projected to reach $95 billion by 2030 and potentially expand to $120 billion by 2035, highlighting the significant growth opportunity in this sector [8] - Pfizer's CEO has indicated that weight loss drugs could become a major product for the company, with potential annual sales reaching $10 billion, making acquisitions a practical strategy in the face of internal development challenges [9]

Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases. ...

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, tod ...

12月11日至13日，由每日经济新闻与海南国际经济发展局联合主办的"2025第十四届上市公司发展年会 暨海南自贸港开放机遇交流大会"系列活动在海口举行。在海南全岛封关进入倒计时之际，超过400家上 市公司与多家机构齐聚，共同探讨高水平开放背景下的政策路径与全球化机遇。 会后，辉瑞中国区副总裁、市场准入部总经理钱云接受了《每日经济新闻》记者专访，就中国创新药政 策环境、商业医疗保险发展以及海南自贸港带来的产业机遇等话题分享了洞察。 "从正式批准之前的先行先试，到加速正式审批，越来越多的创新药可以实现全球同步上市，并且在上 市当年争取进入医保目录，这极大加快了创新药进入中国和真正落地的步伐。过去在相当长一段时期 内，创新药的'最后一公里'问题仍然是限制创新药速度的重要因素，而随着医疗机构提高药事会召开频 次、双通道以及今年首版商保目录的推出，都让创新药提升了从研发端到患者端的速度与效率。" 海南"试验田"价值凸显：乐城已成创新药先行先试重要窗口 正如钱云所说，商保目录的推出是一个让产业为之振奋的信号。在钱云看来，此前的基本医保、大病保 险、商业保险等构筑了一个多维度的患者保障计划。"比如在某个城市，一款罕见病药物 ...

Core Insights - The "High Income DIY Portfolios" service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees [1][2] - The service offers a total of 10 model portfolios, including various strategies like buy-and-hold and rotational portfolios, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1: Portfolio Strategies - The service includes seven portfolios: three buy-and-hold, three rotational, and a conservative NPP strategy portfolio, focusing on low drawdowns and high growth [1] - The portfolios are categorized into two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy [1] Group 2: Investment Approach - The investment approach emphasizes a unique 3-basket strategy that targets 30% lower drawdowns and aims for a 6% current income with market-beating growth over the long term [2] - The service provides buy and sell alerts, as well as live chat for real-time support and guidance [2]

Group 1 - Teladoc Health has been struggling with declining revenue as demand for its services has decreased post-pandemic, and its virtual therapy service, BetterHelp, faces stiff competition [1] - Management efforts to turn around Teladoc have not been successful, leading to a recommendation for investors to consider other healthcare stocks, particularly Pfizer [2] - Pfizer experienced significant revenue and earnings growth during the pandemic due to its leading coronavirus vaccine, Comirnaty, and antiviral treatment, Paxlovid, but has seen a decline in revenues over the past three years [4] Group 2 - Despite a 50% decline in share price over the past three years, Pfizer has a clearer path to recovery compared to Teladoc, supported by its established profit generation and strategic acquisitions [5] - Pfizer is expected to secure approvals for several new products in the coming years, targeting markets such as weight management and oncology, which are crucial for future sales and earnings growth [6] - The company has over 100 programs in clinical trials and has taken steps to mitigate potential threats, including a deal to sell some medicines at lower prices in exchange for tariff exemptions [7]

Core Viewpoint - Pfizer's aggressive strategy in the weight loss drug market is underscored by its recent licensing agreement with Fosun Pharma, granting Pfizer exclusive global rights to develop and commercialize the oral GLP-1R agonist YP05002, with a total transaction value of up to $2.085 billion [1][3][4]. Group 1: Pfizer's Strategic Moves - Pfizer's recent acquisition of Metsera for over $10 billion and the licensing deal for YP05002 reflect its commitment to expanding its weight loss drug portfolio amid impending patent expirations for several key products [3][4]. - The company plans to invest $10-15 billion in mergers and acquisitions by 2025, indicating a proactive approach to filling revenue gaps caused by patent cliffs [3][4]. - Pfizer's recent transactions highlight its determination to capture a significant share of the weight loss market, which is projected to be worth hundreds of billions [3][4]. Group 2: Fosun Pharma's International Strategy - The collaboration with Pfizer is a significant milestone for Fosun Pharma, enhancing its internationalization strategy and accelerating the global development of YP05002 [2][10]. - Fosun Pharma has completed six external business development deals in 2025, totaling approximately $4 billion, which includes various innovative drug pipelines [10][11]. - The partnership with Pfizer not only boosts Fosun's revenue potential but also strengthens its core technology platforms in antibody, ADC, cell therapy, and small molecule innovation [10][11]. Group 3: Market Dynamics and Competitors - The weight loss drug market is experiencing a surge, with multiple companies reporting positive clinical data for their GLP-1 drugs, leading to significant stock price increases [5][6]. - Notable competitors include ShouTi Bio and EQRx, which have reported promising results for their respective GLP-1 drugs, indicating a competitive landscape [5][6]. - The emergence of next-generation weight loss drugs, including small molecules and siRNA therapies, suggests a dynamic and evolving market with various players vying for market share [8][9][14].

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to brin. ...

Keep your expectations in check.It now seems so long ago that Pfizer (PFE +0.50%) became the first company in the biopharmaceutical industry to generate over $100 billion in annual sales. The drugmaker achieved this milestone thanks to its dominance in the coronavirus vaccine market. However, this niche has since shrunk considerably -- and it could become even smaller next year. Regulators in the U.S. are making it harder for healthy individuals to get vaccinated.Pfizer needs a way to replace this dwindling ...